These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30711954)

  • 1. Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
    Lee SJ; Jeong JH; Lee IH; Lee J; Jung JH; Park HY; Lee DH; Chae YS
    Anticancer Res; 2019 Feb; 39(2):751-758. PubMed ID: 30711954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
    Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
    Asano M; Matsui J; Towle MJ; Wu J; McGonigle S; DE Boisferon MH; Uenaka T; Nomoto K; Littlefield BA
    Anticancer Res; 2018 Jun; 38(6):3375-3385. PubMed ID: 29848686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
    Sakaguchi K; Nakatsukasa K; Koyama H; Kato M; Sakuyama A; Matsuda T; Tsunoda N; Fujiwara I; Yamaguchi M; Tanaka H; Onishi K; Onishi M; Yoshino Y; Kikuchi T; Taguchi T
    Anticancer Res; 2018 Jul; 38(7):4073-4081. PubMed ID: 29970533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
    Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Fujita H; Takashima T; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
    Anticancer Res; 2019 Aug; 39(8):4031-4041. PubMed ID: 31366485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen and tranilast show a synergistic effect against breast cancer in vitro.
    Darakhshan S; Ghanbari A; Gholami Rad F; Bidmeshki Pour A
    Bratisl Lek Listy; 2015; 116(1):69-73. PubMed ID: 25666966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
    Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
    PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.
    Araki K; Fukada I; Yanagi H; Kobayashi K; Shibayama T; Horii R; Takahashi S; Akiyama F; Ohno S; Ito Y
    Breast; 2017 Oct; 35():78-84. PubMed ID: 28662406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anticancer effects of a bioactive subfraction of Strobilanthes crispus and tamoxifen on MCF-7 and MDA-MB-231 human breast cancer cell lines.
    Yaacob NS; Kamal NN; Norazmi MN
    BMC Complement Altern Med; 2014 Jul; 14():252. PubMed ID: 25034326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
    Casanova C; Verlicchi A; Mazza V; Dazzi C
    Future Oncol; 2015; 11(15 Suppl):9-15. PubMed ID: 26235259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells.
    Khamis AAA; Ali EMM; El-Moneim MAA; Abd-Alhaseeb MM; El-Magd MA; Salim EI
    Biomed Pharmacother; 2018 Sep; 105():1335-1343. PubMed ID: 30021371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
    Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
    Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
    Oba T; Izumi H; Ito KI
    Oncotarget; 2016 Oct; 7(43):70011-70027. PubMed ID: 27588398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
    Zhang WJ; Xu DF; Fan QX; Wu XA; Wang F; Wang R; Wang LX
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):645-51. PubMed ID: 23159075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
    Smollich M; Götte M; Fischgräbe J; Macedo LF; Brodie A; Chen S; Radke I; Kiesel L; Wülfing P
    Breast Cancer Res Treat; 2010 Sep; 123(2):345-57. PubMed ID: 19943105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.